PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme.

Jakub Litak,Paweł Krukow,Wiesława Grajkowska,Ryszard Maciejewski,Jacek Roliński,Cezary Grochowski,Justyna Szumiło

doi:10.3390/brainsci11020262

Jakub Litak, Paweł Krukow + Show 5 more

Open Access

https://doi.org/10.3390/brainsci11020262

Copy DOI

Abstract

High-grade gliomas are infrequent in the pediatric population compared to adults, nevertheless, mortality and morbidity caused by malignant gliomas in this group of patients remain significant. PD-L1 and PD-1 Immune checkpoints (IC) molecules maintain immunological balance between activation and suppression. Eighteen patients with a histopathological diagnosis of pediatric glioblastoma multiforme (GBM, WHO IV) were studied. In total, PD-L1 expression was detected in 8 patients (44%). The molecular aspect of IC and immunotherapy targeted on PD-1/PD-L1 axis in pediatric population may be a promising adjuvant therapy in pediatric glioblastoma multiform treatment, however, this subject requires further investigation.

Highlights

High-grade gliomas are infrequent in the pediatric population compared to adults, mortality and morbidity caused by malignant gliomas in this group of patients remain significant
Glioblastoma Multiforme patients older than 3 years of age are treated with surgery, adjuvant chemo and radiotherapy
The presented study revealed that PD-L1 expression is present in pediatric glioblastoma multiforme patients

Summary

Introduction

High-grade gliomas are infrequent in the pediatric population compared to adults, mortality and morbidity caused by malignant gliomas in this group of patients remain significant. The incidence of high-grade gliomas is 10%. GBM incidence varies between 3 and 15% of all primary central nervous system tumors. The five year survival time for pediatric patients is ca. Glioblastoma Multiforme patients older than 3 years of age are treated with surgery, adjuvant chemo and radiotherapy. In younger patients’ radiotherapy should be delayed to avoid significant adverse effects affecting the developing brain tissue. Optimal therapeutic strategy is still uncertain [2]. Current studies point at molecular aspects of the underlying neoplastic processes as the target of modern therapies [3,4]

Methods

Results

Discussion

Conclusion